UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer

뉴스 본문을 불러오고 있어요.

UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer | 웨이프 WAPE

UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer

기사 요약

관련 종목

댓글 —